English NHS must fund value based pricing system drugs
This article was originally published in Scrip
Executive Summary
England's Department of Health yesterday gave pharmaceutical companies a little more clarity on what the new value-based pricing system might have in store when it confirmed that the National Health Service in England will have to fund drugs that are subject to the new system. The news could mean fewer barriers than anticipated to the uptake of new medicines. Nevertheless the BioIndustry Association (BIA), representing UK biotech firms, warned that the new system could make the UK a less attractive location to launch medicines.